ArticlePediatrics2020
Prenatal Antidepressant Use and Risk of Adverse Neonatal Outcomes.
Article in Pediatrics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 45 citations in OpenAlex.
- PregMedNet: Multifaceted maternal medication impacts on neonatal complications.Nature communications · 2026Article
- Depression and antidepressant treatment in growing up in New Zealand: impact on preterm birth and low birth weight.Archives of women's mental health · 2026Article
- Placental and fetal consequences of maternal selective serotonin reuptake inhibitor use: current evidence and unresolved questions.Frontiers in pharmacology · 2026Review
- PregMedNet: Multifaceted Maternal Medication Impacts on Neonatal Complications.medRxiv : the preprint server for health sciences · 2025Article
- Prenatal treatment with the antidepressant fluoxetine on maternal and neonatal behavior in sheep.Pediatric research · 2025Article
- Progress in the study of the effects of selective serotonin reuptake inhibitors (SSRIs) on the reproductive system.Frontiers in pharmacology · 2025Review
- Potential adverse events of fluoxetine: a real-world study based on the FAERS database.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) · 2025Article
- Timing of selective serotonin reuptake inhibitor use and risk for preterm birth and related adverse events: with a consideration of the COVID-19 pandemic period.The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians · 2024Article
- Maternal treatment with selective serotonin reuptake inhibitors during pregnancy and delayed neonatal adaptation: a population-based cohort study.Archives of disease in childhood. Fetal and neonatal edition · 2024Article
- Selective serotonin reuptake inhibitors during pregnancy and lactation: A scoping review of effects on the maternal and infant gut microbiome.Developmental psychobiology · 2024Article
- The antidepressant fluoxetine (Prozac®) modulates serotonin signaling to alter maternal peripartum calcium homeostasis.Scientific reports · 2023Article
- Maternal serotonin: implications for the use of selective serotonin reuptake inhibitors during gestation†.Biology of reproduction · 2023Review
- Comment on: "Should Antidepressants be Avoided in Pregnancy?"Drug safety · 2023Article
- Maternal comorbidity and adverse perinatal outcomes in survivors of adolescent and young adult cancer: A cohort study.BJOG : an international journal of obstetrics and gynaecology · 2023Article
- Associations between antidepressant use patterns during pregnancy and birth outcomes among periconception antidepressant users.Pharmacotherapy · 2023Article
- The antidepressant fluoxetine (Prozac®) modulates estrogen signaling in the uterus and alters estrous cycles in mice.Molecular and cellular endocrinology · 2023Article
- Longitudinal Methods for Modeling Exposures in Pharmacoepidemiologic Studies in Pregnancy.Epidemiologic reviews · 2022Review
- Sudden Onset of Severe Pulmonary Hypertension in a Preterm Infant: A Case Report on the Role of Maternal Use of Serotonin Re-Uptake Inhibitors During Pregnancy and Concurrent Risk Factors.Frontiers in pediatrics · 2022Article
- Article
- Trajectories of Prescription Opioid Utilization During Pregnancy Among Prepregnancy Chronic Users and Risk of Neonatal Opioid Withdrawal Syndrome.American journal of epidemiology · 2022Article
Corrections and comments
- Commented on by
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
objectivesTo estimate the risk of neonatal outcomes from patterns of prenatal antidepressant use.
methodsFrom the OptumLabs Data Warehouse, 226 932 singleton deliveries were identified. Antidepressant claims with coverage between the last menstrual period and 35 weeks' gestation were converted to fluoxetine equivalents, and a longitudinal cluster analysis was performed. Outcomes included major cardiac malformations (11.7 of 1000 births), preterm birth (75.7 of 1000 births), and newborn respiratory distress (54.2 of 1000 births). The lowest trajectory was the primary reference group, and depression and anxiety with no antidepressant claims served as secondary reference groups.
resultsFrom 15 041 (6.6%) pregnancies exposed to an antidepressant, use patterns were best described as (1) low use (∼10 mg/day) with first-trimester reduction, (2) low sustained use (∼20 mg/day), (3) moderate use (∼40 mg/day) with first-trimester reduction, (4) moderate sustained use (∼40 mg/day), and (5) high sustained use (∼75 mg/day). Moderate sustained use increased the risk of major cardiac malformations, although results included the null when compared with depression or anxiety reference groups. Moderate sustained (adjusted risk ratio [RR] 1.31; 95% confidence interval [CI] 1.16-1.49) and high sustained (adjusted RR 1.78; 95% CI 1.48-2.14) trajectories were associated with an increased risk of preterm birth. All 4 trajectories increased the risk of neonatal respiratory distress in a dose-response fashion (adjusted RRs 1.36 [95% CI 1.20-1.50] to 2.23 [95% CI 1.83-2.77]).
conclusionsAlthough findings support continuation of the lowest effective dose to treat depression or anxiety, which benefits the mother, they also highlight an increased risk for newborn respiratory distress in all groups and preterm birth at moderate to high sustained doses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.